Shots:
- Arrowhead has reported topline P-III (SHASTA-3 & 4) trial results assessing plozasiran (25mg, SC, Q3M) vs PBO in sHTG pts (n=~750), where both trials met their 1EP of reduced median TGs by 79% & 81%, respectively, at 12mos. vs ~27%
- Pooled analyses showed significant reductions in AP event rates & total incidence rate, with cumulative AP events reduced by 78% in broad sHTG (TGs>500mg/dL, regardless of AP history) & 100% in the highest-risk subgroup (TGs>880mg/dL, with AP history); data to be presented at ESC’26
- Arrowhead plans to use data from the SHASTA-3, SHASTA-4, & MUIR-3 studies to seek sHTG marketing authorization globally, beginning with a planned US FDA sNDA submission by the end of 2026
Ref: Businesswire | Image: Arrowhead | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
